Streptococcal Pneumonia - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Streptococcal Pneumonia - Pipeline Review, H1 2016

Streptococcal Pneumonia - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Streptococcal Pneumonia - Pipeline Review, H1 2016
Published Jun 08, 2016
139 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Streptococcal Pneumonia - Pipeline Review, H1 2016, provides an overview of the Streptococcal Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Streptococcal Pneumonia
- The report reviews pipeline therapeutics for Streptococcal Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Streptococcal Pneumonia therapeutics and enlists all their major and minor projects
- The report assesses Streptococcal Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Streptococcal Pneumonia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding

  
Source:
Document ID
GMDHC8165IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Streptococcal Pneumonia Overview121
Therapeutics Development132
  Pipeline Products for Streptococcal Pneumonia Overview131
  Pipeline Products for Streptococcal Pneumonia Comparative Analysis141
Streptococcal Pneumonia Therapeutics under Development by Companies152
Streptococcal Pneumonia Therapeutics under Investigation by Universities/Institutes171
Streptococcal Pneumonia Pipeline Products Glance183
  Late Stage Products181
  Clinical Stage Products191
  Early Stage Products201
Streptococcal Pneumonia Products under Development by Companies212
Streptococcal Pneumonia Products under Investigation by Universities/Institutes231
Streptococcal Pneumonia Companies Involved in Therapeutics Development2428
  Abera Bioscience AB241
  Actelion Ltd251
  Alvogen Korea Co., Ltd.261
  Arsanis Biosciences GmbH271
  AstraZeneca Plc281
  Beijing Minhai Biotechnology Co., Ltd291
  ContraFect Corporation301
  Daiichi Sankyo Company, Limited311
  Eurocine Vaccines AB321
  FluGen, Inc.331
  GlaxoSmithKline Plc341
  ImmunoBiology Limited351
  Lascco SA361
  Liquidia Technologies, Inc.371
  Merck &Co., Inc.381
  Mucosis B.V.391
  Panacea Biotec Limited401
  Prometheon Pharma, LLC411
  Sanofi Pasteur SA421
  Serum Institute of India Limited431
  SK Chemicals Co., Ltd.441
  Sumitomo Dainippon Pharma Co., Ltd.451
  Valneva SE461
  Vaxxilon AG471
  Virometix AG481
  Walvax Biotechnology Co., Ltd.491
  Wellstat Vaccines, LLC501
  Wockhardt Limited511
Streptococcal Pneumonia Therapeutics Assessment5210
  Assessment by Monotherapy Products521
  Assessment by Combination Products531
  Assessment by Target542
  Assessment by Mechanism of Action562
  Assessment by Route of Administration582
  Assessment by Molecule Type602
Drug Profiles6258
  (Streptococcal pneumonia + typhoid) vaccine - Drug Profile621
    Product Description621
    Mechanism of Action621
    R&D Progress621
  Ab-01 - Drug Profile631
    Product Description631
    Mechanism of Action631
    R&D Progress631
  ACT-292706 - Drug Profile641
    Product Description641
    Mechanism of Action641
    R&D Progress641
  ACT-387042 - Drug Profile651
    Product Description651
    Mechanism of Action651
    R&D Progress651
  ASN-400 - Drug Profile661
    Product Description661
    Mechanism of Action661
    R&D Progress661
  AZ-6142 - Drug Profile671
    Product Description671
    Mechanism of Action671
    R&D Progress671
  CAL-02 - Drug Profile681
    Product Description681
    Mechanism of Action681
    R&D Progress681
  CF-303 - Drug Profile691
    Product Description691
    Mechanism of Action691
    R&D Progress691
  CF-309 - Drug Profile701
    Product Description701
    Mechanism of Action701
    R&D Progress701
  DEF-201 - Drug Profile711
    Product Description711
    Mechanism of Action711
    R&D Progress712
  GSK-2189242A - Drug Profile731
    Product Description731
    Mechanism of Action731
    R&D Progress731
  LCB-010371 - Drug Profile741
    Product Description741
    Mechanism of Action741
    R&D Progress742
  Monoclonal Antibodies for Pneumococcus Infections - Drug Profile761
    Product Description761
    Mechanism of Action761
    R&D Progress761
  Monoclonal Antibodies to Inhibit ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile771
    Product Description771
    Mechanism of Action771
    R&D Progress771
  Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Neurodegenerative Diseases - Drug Profile781
    Product Description781
    Mechanism of Action781
    R&D Progress781
  NBP-606 - Drug Profile791
    Product Description791
    Mechanism of Action791
    R&D Progress791
  Nucovac - Drug Profile801
    Product Description801
    Mechanism of Action801
    R&D Progress801
  PneuGEM - Drug Profile811
    Product Description811
    Mechanism of Action811
    R&D Progress811
  pneumococcal (13-valent) vaccine - Drug Profile821
    Product Description821
    Mechanism of Action821
    R&D Progress821
  pneumococcal (13-valent) vaccine - Drug Profile831
    Product Description831
    Mechanism of Action831
    R&D Progress831
  pneumococcal (13-valent) vaccine - Drug Profile841
    Product Description841
    Mechanism of Action841
    R&D Progress841
  pneumococcal (23-valent) vaccine - Drug Profile851
    Product Description851
    Mechanism of Action851
    R&D Progress851
  pneumococcal (23-valent) vaccine - Drug Profile861
    Product Description861
    Mechanism of Action861
    R&D Progress861
  pneumococcal [serotype 4, 6A] vaccine - Drug Profile871
    Product Description871
    Mechanism of Action871
    R&D Progress871
  pneumococcal [strain TIGR4] vaccine - Drug Profile881
    Product Description881
    Mechanism of Action881
    R&D Progress881
  pneumococcal vaccine - Drug Profile891
    Product Description891
    Mechanism of Action891
    R&D Progress891
  pneumococcal vaccine - Drug Profile901
    Product Description901
    Mechanism of Action901
    R&D Progress901
  pneumococcal vaccine - Drug Profile911
    Product Description911
    Mechanism of Action911
    R&D Progress911
  pneumococcal vaccine - Drug Profile921
    Product Description921
    Mechanism of Action921
    R&D Progress921
  pneumococcal vaccine - Drug Profile931
    Product Description931
    Mechanism of Action931
    R&D Progress931
  pneumococcal vaccine - Drug Profile941
    Product Description941
    Mechanism of Action941
    R&D Progress941
  pneumococcal vaccine - Drug Profile951
    Product Description951
    Mechanism of Action951
    R&D Progress951
  pneumococcal vaccine - Drug Profile961
    Product Description961
    Mechanism of Action961
    R&D Progress961
  PneumoMab - Drug Profile971
    Product Description971
    Mechanism of Action971
    R&D Progress971
  pneumonia vaccine - Drug Profile981
    Product Description981
    Mechanism of Action981
    R&D Progress981
  PnuBioVax - Drug Profile991
    Product Description991
    Mechanism of Action991
    R&D Progress991
  PPV-23 - Drug Profile1001
    Product Description1001
    Mechanism of Action1001
    R&D Progress1001
  SIILPCV-10 - Drug Profile1011
    Product Description1011
    Mechanism of Action1011
    R&D Progress1011
  SM-295291 - Drug Profile1021
    Product Description1021
    Mechanism of Action1021
    R&D Progress1021
  SM-369926 - Drug Profile1031
    Product Description1031
    Mechanism of Action1031
    R&D Progress1031
  Small Molecule for Respiratory Tract Infections - Drug Profile1041
    Product Description1041
    Mechanism of Action1041
    R&D Progress1041
  Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile1051
    Product Description1051
    Mechanism of Action1051
    R&D Progress1051
  Small Molecules for Streptococcus Pneumoniae Infections - Drug Profile1061
    Product Description1061
    Mechanism of Action1061
    R&D Progress1061
  Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile1071
    Product Description1071
    Mechanism of Action1071
    R&D Progress1071
  streptococcal pneumonia vaccine - Drug Profile1081
    Product Description1081
    Mechanism of Action1081
    R&D Progress1081
  Streptococcal pneumonia vaccine - Drug Profile1091
    Product Description1091
    Mechanism of Action1091
    R&D Progress1091
  Streptococcal pneumonia vaccine - Drug Profile1101
    Product Description1101
    Mechanism of Action1101
    R&D Progress1101
  Streptococcal pneumonia vaccine 3 - Drug Profile1111
    Product Description1111
    Mechanism of Action1111
    R&D Progress1111
  Streptococcus pneumonia (whole-cell) vaccine - Drug Profile1121
    Product Description1121
    Mechanism of Action1121
    R&D Progress1122

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Streptococcal Pneumonia - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Streptococcal-Pneumonia-Pipeline-Review-H1-2016-2088-15908>
  
APA:
Global Markets Direct - Market Research. (2016). Streptococcal Pneumonia - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Streptococcal-Pneumonia-Pipeline-Review-H1-2016-2088-15908>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.